Arimoclomol offers new hope in the treatment of NPC with significant efficacy

Arimoclomol(arimoclomol, trade nameMiplyffa) is an innovative New oral medications to be released in2024year9month20 was recently approved by the U.S. Food and Drug Administration (FDA) and became the first drug for the treatment of neurological symptoms related to C Niemann-Pick disease (NPC), marking a major breakthrough in the treatment of NPC this rare disease.

NPC is a rare genetic disease caused by mutations in the NPC1 or NPC2 genes, which results in abnormal intracellular transport of cholesterol and other lipids, leading to progressive neurological symptoms and organ dysfunction. The average lifespan of patients is only about 13 years, so the approval of arelomol brings a new dawn to patients and their families.

Arelomol needs to be used in combination with the enzyme inhibitor miglustat (miglustat), which is suitable for adults and pediatric patients 2 years old and above. Its efficacy and safety were fully verified in a 12-month randomized, double-blind, placebo-controlled trial. The trial included 50people aged 2 to 19 between pan> years old were randomly assigned to the arelomol treatment group or the placebo group according to the ratio of 2:1.

Trial results show that arelomol has significant efficacy in slowing disease progression. This efficacy was strongly confirmed by the rescored 4domainNPC Clinical Severity Scale (R4DNPCCSS ). R4DNPCCSSEvaluates key functions such as walking, speaking, swallowing and fine motor skills, with higher scores indicating more severe disease. Patients treated with arelomol had significantly slower disease progression compared with those treated with placebo.

Although arelomol has shown significant efficacy in the treatment of NPC, its use may also be associated with some side effects. The most common side effects include upper respiratory tract infection, diarrhea, and weight loss. In addition, the prescribing information for arelomol contains a warning about allergic reactions, such as urticaria and angioedema, and patients should discontinue the drug immediately if these reactions occur.

Of note, women who are pregnant or planning to become pregnant should avoid the use of arelomol as its safety to the fetus has not been established. The recommended dose of arelomol is adjusted based on patient weight and can be taken orally with or without food.

The combined use of arelomol and milglulast provides a new treatment option for NPC patients, filling the treatment gap in the field of this rare disease. Overall, the approval of arelomol not only brings significant clinical benefits to NPC patients, but also sets an important milestone for the development and approval of rare disease drugs. In the future, with the accumulation of more clinical data and in-depth research, arelomol is expected to bring hope and good news to more NPC patients.

Reference link: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c